Miklos Diossy
Overview
Explore the profile of Miklos Diossy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diossy M, Tisza V, Li H, Sahgal P, Zhou J, Sztupinszki Z, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):208.
PMID: 39294262
We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain...
2.
Prosz A, Sahgal P, Huffman B, Sztupinszki Z, Morris C, Chen D, et al.
NPJ Precis Oncol
. 2024 May;
8(1):98.
PMID: 38710943
No abstract available.
3.
Szallasi Z, Diossy M, Tisza V, Li H, Sahgal P, Zhou J, et al.
Res Sq
. 2024 Apr;
PMID: 38645014
We analyzed genomic data derived from the prostate cancer of African and European American men in order to identify differences that may contribute to racial disparity of outcome and that...
4.
Prosz A, Sahgal P, Huffman B, Sztupinszki Z, Morris C, Chen D, et al.
NPJ Precis Oncol
. 2024 Apr;
8(1):87.
PMID: 38589664
Homologous recombination (HR) and nucleotide excision repair (NER) are the two most frequently disabled DNA repair pathways in cancer. HR-deficient breast, ovarian, pancreatic and prostate cancers respond well to platinum...
5.
Baca S, Seo J, Davidsohn M, Fortunato B, Semaan K, Sotudian S, et al.
Nat Med
. 2023 Dec;
30(3):907.
PMID: 38049623
No abstract available.
6.
Prosz A, Duan H, Tisza V, Sahgal P, Topka S, Klus G, et al.
Sci Rep
. 2023 Nov;
13(1):20567.
PMID: 37996508
Due to a demonstrated lack of DNA repair deficiencies, clear cell renal cell carcinoma (ccRCC) has not benefitted from targeted synthetic lethality-based therapies. We investigated whether nucleotide excision repair (NER)...
7.
Baca S, Seo J, Davidsohn M, Fortunato B, Semaan K, Sotudian S, et al.
Nat Med
. 2023 Oct;
29(11):2737-2741.
PMID: 37865722
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and...
8.
Prosz A, Duan H, Tisza V, Sahgal P, Topka S, Klus G, et al.
bioRxiv
. 2023 Feb;
PMID: 36798363
Purpose: Due to a demonstrated lack of DNA repair deficiencies, clear cell renal cell carcinoma (ccRCC) has not benefitted from targeted synthetic lethality-based therapies. We investigated whether nucleotide excision repair...
9.
Plym A, Diossy M, Szallasi Z, Sartor O, Silberstein J, Powell I, et al.
JNCI Cancer Spectr
. 2022 Jan;
6(1).
PMID: 35079693
Background: Altered DNA damage response (DDR) has emerged as an important mechanism for the development of aggressive prostate cancer among men of European ancestry but not other ancestry groups. Because...
10.
He Y, Rivera J, Diossy M, Duan H, Bowman-Colin C, Reed R, et al.
Proc Natl Acad Sci U S A
. 2021 Oct;
118(41).
PMID: 34607954
germline mutations are associated with an increased risk of breast and ovarian cancer. Recent findings of others suggest that mutation carriers also bear an increased risk of esophageal and gastric...